Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd has published a newspaper advertisement for their unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as per Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd has announced its unaudited financial results for Q1FY27, showing a challenging quarter due to subdued demand, geopolitical uncertainty, and raw material market volatility. The company's revenue, EBITDA, and PAT have declined YoY by 42%, 54%, and 68%, respectively. The CRAMS pipeline remains on track, and the company expects a meaningful improvement in performance in the second half of FY27.

Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd reported Q1FY27 results with revenue down 42% YoY and PAT down 68% YoY due to subdued European demand and raw material volatility. The company expects a timing issue in the second half of FY27 but remains confident in its long-term growth prospects.

Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd has announced the appointment of Cost Auditors for the year 2026-2027 and the unaudited financial results for the quarter ended June 30, 2026.

Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, along with the appointment of a new cost auditor and other board decisions.

Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, and has also appointed M/s. M. I. Prajapati & Associates LLP as Cost Auditors for the year 2026-2027.

Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve the Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended on June 30, 2026.